noninvasive ventilation, intravenous (IV) fl uids, and blood products and was started on IV ceftriaxone, artesunate, and oral doxycycline. As her clinical picture matched with the clinical presentation of CCHF and her condition deteriorated despite appropriate therapy, blood samples were sent to the National Centre for Disease Control, New Delhi for CCHF serology testing. She tested positive for CCHF disease specifi c genes by reverse transcription-polymerase chain reaction (RT-PCR). The patient was started on oral ribavirin 1000 mg every 6 h (via naso -gastric tube). Over the next 2 days, the patient developed worsening multi organ failure and succumbed to her illness. Around 20 hospital staff were inadvertently exposed to the patient, of which 16 had close contact with her or had handled blood and urine samples. All were started on ribavirin prophylaxis as per the recommended doses. The drug was poorly tolerated by most and had to be stopped prematurely as most could not tolerate the prescribed dose. Contact tracing was carried out, but thankfully none of the family members developed the disease. One of the hospital staff were she was admitted prior to our unit, developed a similar illness, which resolved with supportive management. We do not know about the CCHF seropositivity of that person.
Discussion
CCHF, is highly contagious and is associated with high mortality, ranging from 10% to 50%. [1] The virus which causes CCHF is a Nairovirus, which is transmitted by ixodid ticks in animals. Humans acquire the virus from direct contact with blood or other infected tissues from livestock having viremia, or they may become infected from a tick bite. The majority of cases have occurred in those involved with the livestock industry, such as veterinarians, agricultural, and slaughterhouse workers. CCHF can be transmitted from one infected human to another by contact with infectious blood or body fl uids. [2] Clinical and laboratory features of patients with CCHF mimic the most prevalent diseases, such as dengue, malaria, and scrub typhus which are commonly encountered in routine practice. As CCHF is usually not considered as the primary cause of fever with rash and pancytopenia in our patients, it is often diagnosed late. This leads to a higher mortality and exposes more health care workers to the disease. Classical clinical features include high grade fever with chills, headache, myalgia, generalized rash, and bleeding. [3] Over the next few days, the patient may experience neurological features, such as mood swings, and may become agitated. After 2-4 days, the agitation may be replaced by mental obtundation and altered sensorium.
Laboratory diagnosis of a patient with a clinical history compatible with CCHF can be made during the acute phase of the disease by using the combination of detection of the viral antigen (ELISA antigen capture), viral RNA sequence (RT-PCR) in the blood or in tissues collected from a fatal case and virus isolation. Later in the course of the disease, in people surviving, antibodies can be found in the blood. [3] General supportive therapy and maintenance of vital parameters is the mainstay of patient management in CCHF. Blood component replacement and hydration are usually required. Ribavirin has been used in the treatment of established CCHF infection with apparent benefi t. [4] Both oral and IV formulations seem to be effective.
Patients with suspected or confi rmed CCHF should be isolated and cared for using barrier nursing techniques. Specimens of blood or tissues taken for diagnostic purposes should be handled using universal precautions. Hospital equipment and body wastes should be safely disposed of using appropriate decontamination procedures.
If strict precautions are not taken, there is a risk of nosocomial spread of infection and it is imperative that adequate infection control measures be observed to contain the infection. Healthcare workers who have had contact with tissue or blood from patients with suspected or confi rmed CCHF should be followed up with daily temperature and symptom monitoring for at least 14 days after the putative exposure.
Outbreaks of CCHF have been reported from India and other regions of the South East Asia earlier [5] and have been associated with high mortality. Most of these cases, like our patient, were diagnosed late, as CCHF was not initially considered as a differential diagnosis. CCHF should be considered in patients with compatible clinical and laboratory features, so that early ribavirin therapy may be started, and appropriate control measures are taken to prevent nosocomial and community spread of the disease.
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